Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13753809 | 0.87 | NPSR1 (0.56) | NPSR1ROCK2ROCK1KDM4EMRGPRX4 | |
| SCHEMBL27273362 | 0.85 | KDM4E (0.57) | NPSR1ROCK2ROCK1KDM4EMRGPRX4 | |
| SCHEMBL23553939 | 0.84 | ROCK2 (0.60) | NPSR1ROCK2ROCK1KDM4EMRGPRX4 | |
| SCHEMBL8593124 | 0.84 | NPSR1 (0.69) | NPSR1ROCK2ROCK1KDM4EATM | |
| SCHEMBL20386704 | 0.83 | NPSR1 (0.56) | NPSR1ROCK2ROCK1KDM4EMRGPRX4 | |
| SCHEMBL1569614 | 0.81 | SLC7A5 (0.60) | MRGPRX4SMYD3CYP4F2CYP4A11KMT2A | |
| SCHEMBL1754131 | 0.81 | ATM (0.67) | NPSR1ATMTAS1R3TAS1R1KMT2A | |
| SCHEMBL30522592 | 0.81 | ATM (0.67) | NPSR1ATMTAS1R3TAS1R1KMT2A | |
| SCHEMBL3305875 | 0.80 | ROCK2 (0.56) | NPSR1ROCK2ROCK1KDM4EMRGPRX4 | |
| SCHEMBL3305869 | 0.80 | ROCK2 (0.56) | NPSR1ROCK2ROCK1KDM4EMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858879-B2 | PARG inhibitors and method of use thereof | CITY OF HOPE (US) | 2024-01-02 | — | — | US | disclosed |
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2019-05-16 | — | — | US | disclosed |
| EP-3428160-A1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | NPSR1 721/4885ROCK2 282/4885ROCK1 373/4885 |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | NPSR1 721/4885ROCK2 282/4885ROCK1 373/4885 |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | NPSR1 721/4885ROCK2 282/4885ROCK1 373/4885 |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | NPSR1 721/4885ROCK2 282/4885ROCK1 373/4885 |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | NPSR1 721/4885ROCK2 282/4885ROCK1 373/4885 |
| US-11858879-B2 | PARG inhibitors and method of use thereof | PARG, PARP12, PARP15 | NPSR1 3995/4885ROCK2 601/4885ROCK1 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.